Chemistry: analytical and immunological testing – Involving an insoluble carrier for immobilizing immunochemicals – Carrier is inorganic
Reexamination Certificate
2008-05-06
2008-05-06
Lam, Ann Y. (Department: 1641)
Chemistry: analytical and immunological testing
Involving an insoluble carrier for immobilizing immunochemicals
Carrier is inorganic
C436S518000
Reexamination Certificate
active
07368295
ABSTRACT:
The present invention relates to nanoparticles with tumor necrosis factor (TNF) or cytokine immobilized thereon, where TNF or the cytokine is preferably immobilized in the form of a trimer in directed fashion and with retention of its biological activity on the carrier, to methods for the directed immobilization of TNF or cytokine on nanoparticles, to the use of the nanoparticles having immobilized TNF or cytokine for the identification and/or isolation of cytokine- or TNF-binding partners and for the identification and/or isolation of inhibitors of the interaction between TNF or cytokine and its binding partners, to the use of such nanoparticles for preparing a pharmaceutical composition, in particular for the therapy of tumors, and to pharmaceutical and diagnostic compositions which comprise such nanoparticles.
REFERENCES:
patent: 6274552 (2001-08-01), Tamarkin et al.
patent: 2003/0082595 (2003-05-01), Jiang et al.
patent: 100 45 592 (2002-03-01), None
patent: 100 45 592 (2002-03-01), None
patent: 0 247 860 (1987-12-01), None
patent: WO 90/09798 (1990-09-01), None
patent: WO 93/12142 (1993-06-01), None
patent: WO 99/62535 (1999-12-01), None
Fassina et al., “Binding of Human Tumor Necrosis Factor alpha to Multimeric Complementary Peptides”, Archives of Biochemistry and Biophysics, vol. 296, No. 1, July, pp. 137-143, 1992.
International Search Report dated Mar. 10, 2003 issued in relation to PCT application No. PCT/EP 02/09185.
“Antitumor Activity of Tumor Necrosis Factor-α Conjugated with Polyvinylpyrrolidone on Solid Tumors in Mice”, Haruhiko Kamada, et al.,Cancer Research60, 6416-6420, Nov. 15, 2000, XP-002231438.
“Treatment with Liposome-Bound Recombinant Human Tumor Necrosis Factor-α Supresses Parasitemia and Protects againstPlasmodium bergheik173-Induced Experimental Cerebral Malaria in Mice”, N.S. Postma, et al.,The Journal of Pharmacology and Experimental Therepeutics, JPET 288:114-120, 1999, XP-002231657.
Preparation and Characterization of Liposomal-Lipophilic Tumor Necrosis Factor, Toshihiko Utsumi, et al.,Cancer Research51, 3362-3366, Jul. 1, 1991, XP-001145748.
“Binding of Human Tumor Necrosis Factor α to Multimeric Complementary Peptides”, Giorgio Fassina, et al.,Archives of Biochemistry and Biophysics, vol. 296, No. 1, July, pp. 137-143, 1992; XP-09003847.
“Enhanced Antitumor Potency of Polyethylene Glycolyated Tumor Necrosis Factor-α: A Novel Polymer-Conjugation Technique with a reversible Amino-Protective Reagent”,Shinichi Tsunoda, et al.,The Journal of Pharmacology and Experimental Therepeutics, JPET 290:368-372, 1999, XP-002231935.
“Cytotoxic and Antitumor Activity of a Recombinant Tumor Necrosis Factor-B1(Fv) Fusion Protein on LeyAntigen-expressing Human Cancer Cells”, Uwe Scherf, et al.,Clinical Cancer Research, vol. 2, 1523-1531, Sep. 1996, XP-000653372.
“A Genetically Modified Recombinant Tumor Necrosis Factor-α Conjugated to the Distal Terminals of Liposomal Surface Grafted Polyethyleneglycol Chains”, Michalakis Savva, et al.,International Journal of Pharmaceutics, 184 (1999) 45-51, XP-001121142.
“Suppression of Syndecan-1 Expression in Endothelial Cells by Tumor Necrosis Factor-α”, Varpu Kainulainen, et al.,The Journal of Biological Chemistry, vol. 271, No. 31, pp. 18759-18766, Aug. 2, 1996, XP-002231936.
“Gelatin Beads as Platforms for Targeting Molecule and Anti-Fas Antibody: Two Major Properties of Cytotoxic T Lymphocytes”, Toshiya Yokozawa, et al.,Experimental Hematology, 28 (2000) 1129-1136.
“Analysis for TNF-α Using Solid-Phase Affinity Capture with Radiolabel and MALDI-MS Detection”. Gregory B. Hurst, et al.,Analytical Chemistry, vol. 71, No. 20, Oct. 15, 1999, 4727-4733.
“Suppression of Syndecan-1 Expression in Endothelial Cells by Tumor Necrosis Factor-α”, Varpu Kainulainen, et al.,The Journal of Biological Chemistry, vol. 271, No. 31, pp. 18759-18766, Aug. 2, 1996.
“In Vitro and In Vivo Release Properties of Brilliant Blue and Tumour Necrosis Factor-Alpha (TNF-α) From Poly (D,L-lactic-co-glycolic acid) Multiphase Microspheres”, M. Iwata, et al.,Journal of Microencapsulation, 1999, vol. 16, No. 6, 777-792.
“Ability of Cell-Sized Beads Bearing Tumor Cell Membrane Proteins to Stimulate LAK cells to Secrete Interferon-γ and Tumor Necrosis Factor-α”, Anita S.-F. Chong, et al.,Cellular Immunology, 134, 96-110 (1991).
“Kinetic Analysis of TNF-α Oligomer-Monomer Transition by Surface Plasmon Resonance and Immunochemical Methods”, Claudio Poiesi, et al.,Cytokine, vol. 5, No. 6 (Nov. 1993), pp. 539-545.
“Binding of Human Tumor Necrosis Factor α to Multimeric Complementary Peptides”, Giorgio Fassina,Archives of Biochemistry and Biophysics, vol. 296, No. 1, July, pp. 137-143, 1992.
“Antitumor Activity of Tumor Necrosis Factorα Conjugated with Polyvinylpyrrolidone on Solid Tumors in Mice”, Haruhiko Kamada, et al.,Cancer Research60, 6416-6420, Nov. 15, 2000.
Postma et al., Treatment with Liposome-Bound Recombinant Human Tumor Necrosis Factor-α Suppresses Parasitemia and Protects againstPlasmodium bergheik173-Induced Experimental Cerebral Malaria in Mice, The Journal of Pharmacology and Experimental Therapeutics, vol. 288, No. 1, 114-120, 1999.
Tsutomu Arakawa et al., Molecular Weight of Recombinant Human Tumor Necrosis Factor-α, The Journal of Biological Chemistry, vol. 262 No. 16, pp. 7484-7485, Jun. 5, 1987.
Paul Wingfield, et al., Tumour necrosis factor is a compact trimer, FEBS Letters, vol. 211, No. 2, 179-184, Jan. 1987.
Search report dated Mar. 22, 2007.
Brunner Herwig
Grell Matthias
Hammer Angela
Pfizenmaier Klaus
Scheurich Peter
Fraunhofer-Gesellschaft zur Foderung der Angewandten Forschung E
Lam Ann Y.
Ostrolenk Faber Gerb & Soffen, LLP
LandOfFree
Nanoparticles comprising biologically active TNF which is... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nanoparticles comprising biologically active TNF which is..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nanoparticles comprising biologically active TNF which is... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2808886